HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV

Sponsor

University of Athens (Other)

Overall Status

Recruiting

CT.gov ID

NCT05928000

Collaborator

(none)

Enrollment

Location

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study aims to assess the efficacy and safety of bulevirtide (BLV) in chronic hepatitis D patients treated in Greek liver centers.

Condition or Disease	Intervention/Treatment	Phase
Hepatitis D	Drug: Bulevirtide

Detailed Description

Background:

The prevalence of infection with hepatitis D virus (HDV) varies widely among different countries and even among different areas of the same country. Over the last decades, the prevalence of HDV infection was reported to be deceasing in most developed countries in parallel with the decreasing prevalence of chronic infection with hepatitis B virus (HBV). However, migration from countries with high HDV prevalence to countries with low HDV prevalence may have changed the HDV epidemiology in developed countries today. In Greece, the current prevalence of antibodies against HDV (anti-HDV) is approximately 5-6% among HBsAg-positive patients who visit the liver clinics of tertiary centers.

Regardless of HDV prevalence in any country, there is certainly underdiagnosis of HDV infection, since the majority of HBsΑg-positive cases are not screened for HDV. In particular in Greece, the anti-HDV screening rate of HBsAg-positive patients seen at tertiary liver centers does not exceed 50% having great variations among different centers.

It is well established that chronic HDV infection worsens the prognosis of HBsAg-positive patients increasing the risk of progression to cirrhosis and development of hepatocellular carcinoma (HCC). Therefore, there can be dramatic consequences if HDV patients are not diagnosed and thus are not properly managed. Until recently, pegylated interferon-alfa (pegIFNa) was the only agent that could be used for the treatment of patients with chronic hepatitis D. Given that pegIFNa has contraindications and suboptimal safety and tolerability profile, not all chronic hepatitis D patients could be treated or could remain on treatment. In addition, pegIFNa is not effective in all patients who can receive such treatment, whereas a large proportion of patients will experience relapses after the end of pegIFNa treatment.

In July 2020, the European Medicines Agency provided conditional approval for the use of bulevirtide (BLV) in patients with chronic hepatitis D. BLV inhibits the entry of HBV and consequently HDV in the hepatocytes by binding to and inactivating NTCP (Na+-taurocholate cotransporting polypeptide or sodium/bile acid cotransporter), which is a bile salt hepatocyte transporter also serving as HBV/HDV entry transporter by interacting with HBsAg. Due to the absence of effective treatment options for chronic hepatitis D, the approval of BLV was based only on data from phase ΙΙ trials including limited number of patients. Over the last two years, BLV has started to be used in limited countries including Greece and thus the systematic report of real life data on BLV in chronic hepatitis D is of great importance.

Aim:

The aim of this study is to assess the efficacy and safety of bulevirtide (BLV) in chronic hepatitis D patients treated in Greek liver centers.

Patients - Therapy:

This study will include all adult (>16 years old) patients with chronic hepatitis D followed at any of the participating centers who started BLV before the approval of the study protocol. Thus, the decision to use BLV will not be affected by the patient enrollment in the study, All patients will be treated with daily BLV subcutaneous injections of 2 mg, with or without concomitant use of a nucleos(t)ide analogue. Patients with concomitant use of pegylated interferon-alfa can be included.

Participating centers:

The following centers have been invited and agreed to participate in the HERACLIS-BLV study:

Department of Gastroenterology, Medical School of National & Kapodistrian University of Athens, General Hospital of Athens "Laiko";
2nd Department of Internal Medicine, Medical School of National & Kapodistrian University of Athens, General Hospital of Athens "Hippokration";
Gastroenterology Department, General Hospital of Athens "Evangelismos";
4th Department of Internal Medicine, General Hospital of Athens "Evangelismos";
University Department of Internal Medicine, General and Oncology Hospital of Kifisia "Agioi Anargyroi";
Gastroenterology Department, "Agios Savvas" General Anticancer-Oncology Hospital of Athens;
General Hospital Nikaia-Piraeus "Agios Panteleimon", General Hospital of Western Attica Agia Varvara;
Internal Medicine Department, 417 NIMTS (Army Equity Fund Hospital);
Gastroenterology Unit, General Hospital of Athens "Alexandra";
Liver Unit, Euroclinic SA, Athens;
Department of Medicine, and Research Laboratory of Internal Medicine, School of Medicine of University of Thessaly, University Hospital of Larissa;
2nd Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital of Thessaloniki "Hippokratio";
4th Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital of Thessaloniki "Hippokratio";
1st Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis;
Department of Gastroenterology, University Hospital of Patras;
Department of Gastroenterology, University Hospital of Ioannina;
Department of Gastroenterology & Hepatology, University Hospital of Heraklion Crete;
1st Department of Internal Medicine, General Hospital of Rhodes, Greece.

Approvals:

Τhe protocol and the informed consent of this non-interventional study will be approved by the Ethical Committee of each participating hospital. All patients will sign an informed consent form.

Endpoints:

Primary

• Serum HDV RNA decline <2 log10 IU/ml and normal ALT at week 48

Secondary

Serum HDV RNA decline <2 log10 IU/ml and normal ALT at week 96
Undetectable serum HDV RNA at week 48
Undetectable serum HDV RNA at week 96

Enrollment and study duration:

The enrollment period is expected to last 6 months; it is estimated that approximately 60-80 patients will be enrolled. The minimum follow-up will be 24 months after the onset of BLV, but non-final results will be available earlier. Final statistical analyses and manuscript preparation are expected to last 6 months. Thus, the total study duration is estimated to be 36 months.

Methods - Follow-up:

Patients' monitoring will be based on the principles of standard clinical practice according to the existing national recommendations for the treatment of patients with chronic hepatitis

Thus, the patients' enrollment into this study will not affect the standard clinical practice for their management A predefined case report form (CRF) will be used for the collection of patients' data before the onset of BLV treatment. Then, standard clinic-laboratory data will be recorded at 6, 12, 18 and 24 months of BLV therapy. The patients' data at different visits will be recorded retrospectively or prospectively depending on the duration of BLV at their inclusion in this study.

Statistical analysis:

All data will be recorded in a specifically designed CRF and will be entered into a specifically designed Excel form and then SPSS database for analyses.

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

80 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Hellenic Multicenter Real-life Clinical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV

Actual Study Start Date :

May 1, 2023

Anticipated Primary Completion Date :

Nov 30, 2023

Anticipated Study Completion Date :

Dec 30, 2023

Arms and Interventions

Arm	Intervention/Treatment
BLV-treated patients All patients treated with daily Bulevirtide (BLV) subcutaneous injections of 2 mg, with or without concomitant use of a nucleos(t)ide analogue. Patients with concomitant use of pegylated interferon-alfa can be included.	Drug: Bulevirtide BulevIrtide treatment in patients with chronic hepatitis D Other Names: Entecavir Tenofovir Pegasys

Arm

Intervention/Treatment

BLV-treated patients

All patients treated with daily Bulevirtide (BLV) subcutaneous injections of 2 mg, with or without concomitant use of a nucleos(t)ide analogue. Patients with concomitant use of pegylated interferon-alfa can be included.

Drug: Bulevirtide

BulevIrtide treatment in patients with chronic hepatitis D

Other Names:

Entecavir

Tenofovir

Pegasys

Outcome Measures

Primary Outcome Measures

Response at week 48 [Week 48]
Proportion of patients with serum HDV RNA decline >=2 log10 IU/ml and normal ALT

Secondary Outcome Measures

Response at week 96 [Week 96]
Proportion of patients with serum HDV RNA decline >=2 log10 IU/ml and normal ALT
Complete response at week 48 [Week 48]
Proportion of patients with undetectable serum HDV RNA
Complete response at week 96 [Week 96]
Proportion of patients with undetectable serum HDV RNA

Eligibility Criteria

Criteria

Ages Eligible for Study:

16 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

All adult (>16 years old) patients with chronic hepatitis D followed at any of the participating centers
Start of BLV treatment before the approval of the study protocol.
Any patient with or without concomitant use of a nucleos(t)ide analogue. Patients with concomitant use of pegylated interferon-alfa can be included.